Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2011

01-01-2011 | Original Article

Non-Erosive Reflux Disease (NERD), Symptomatic and Asymptomatic Erosive Reflux Disease (ERD): From Hypersensitive to Hyposensitive Esophagus

Authors: Juanda L. Hartono, Choon-Seng Qua, Khean-Lee Goh

Published in: Digestive Diseases and Sciences | Issue 1/2011

Login to get access

Abstract

Aims

To compare the esophageal sensitivity to acid and saline in patients with symptomatic and asymptomatic erosive reflux disease (ERD), non-erosive reflux disease (NERD) and controls, and to assess the response to proton-pump inhibitors in patients with symptomatic ERD and NERD.

Methodology

Patients with GERD and a control group of healthy asymptomatic volunteers were recruited. All subjects underwent esophagogastroduodenoscopy and the acid-saline perfusion test. Symptomatic ERD and NERD patients were given rabeprazole 20 mg twice daily for 2 weeks and their response to treatment assessed.

Results

A total of 105 subjects were recruited: ERD = 37 (symptomatic = 24, asymptomatic = 13), NERD = 34 and controls = 34. During saline perfusion, only the NERD group recorded a significantly higher sensitivity score compared to controls (2.74 ± 7.28 vs. 0) (p = 0.035). During acid perfusion, symptomatic ERD (15.42 ± 13.42) and NERD (16.71 ± 15.04) had significantly higher scores versus controls and asymptomatic ERD patients (both p < 0.001). The mean %∆ reflux symptom score following treatment was significantly higher in symptomatic ERD patients compared to NERD patients (89.08 ± 21.67 vs. 58.53 ± 32.54; p < 0.001).

Conclusions

Patients with NERD were a generally hypersensitive group while asymptomatic ERD patients represent a hyposensitive group of patients which merits further study.
Literature
1.
go back to reference Goh KL. Changing epidemiology of gastroesophageal reflux disease in the Asian-Pacific region: an overview. J Gastroenterol Hepatol. 2004;19(Suppl 3):S22–S25.CrossRefPubMed Goh KL. Changing epidemiology of gastroesophageal reflux disease in the Asian-Pacific region: an overview. J Gastroenterol Hepatol. 2004;19(Suppl 3):S22–S25.CrossRefPubMed
2.
3.
go back to reference Fass R, Ofman JJ. Gastroesophageal reflux disease–should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901–1909.PubMed Fass R, Ofman JJ. Gastroesophageal reflux disease–should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901–1909.PubMed
4.
go back to reference Bernstein LM, Baker LA. A clinical test for esophagitis. Gastroenterology. 1958;34:760–781.PubMed Bernstein LM, Baker LA. A clinical test for esophagitis. Gastroenterology. 1958;34:760–781.PubMed
5.
go back to reference Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.CrossRefPubMed Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.CrossRefPubMed
6.
go back to reference Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998;115:1363–1373.CrossRefPubMed Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998;115:1363–1373.CrossRefPubMed
7.
go back to reference Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000;29:125–130.CrossRefPubMed Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000;29:125–130.CrossRefPubMed
8.
go back to reference Drewes AM, Reddy H, Staahl C, et al. Sensory-motor responses to mechanical stimulation of the esophagus after sensitization with acid. World J Gastroenterol. 2005;11:4367–4374.PubMed Drewes AM, Reddy H, Staahl C, et al. Sensory-motor responses to mechanical stimulation of the esophagus after sensitization with acid. World J Gastroenterol. 2005;11:4367–4374.PubMed
9.
go back to reference Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999;116:1257–1264.CrossRefPubMed Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999;116:1257–1264.CrossRefPubMed
10.
go back to reference Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. Eur Respir J. 2000;16:633–638.CrossRefPubMed Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. Eur Respir J. 2000;16:633–638.CrossRefPubMed
11.
go back to reference Richter JE, Hewson EG, Sinclair JW, Dalton CB. Acid perfusion test and 24-hour esophageal pH monitoring with symptom index. Comparison of tests for esophageal acid sensitivity. Dig Dis Sci. 1991;36:565–571. Richter JE, Hewson EG, Sinclair JW, Dalton CB. Acid perfusion test and 24-hour esophageal pH monitoring with symptom index. Comparison of tests for esophageal acid sensitivity. Dig Dis Sci. 1991;36:565–571.
12.
go back to reference King AL, Anggiansah A, Anggiansah R, Wong T. Acid perfusion test: a useful test for evaluating esophageal acid sensitivity. Dig Dis Sci. 2005;50:1611–1615.CrossRefPubMed King AL, Anggiansah A, Anggiansah R, Wong T. Acid perfusion test: a useful test for evaluating esophageal acid sensitivity. Dig Dis Sci. 2005;50:1611–1615.CrossRefPubMed
13.
go back to reference Jung B, Steinbach J, Beaumont C, Mittal RK. Lack of association between esophageal acid sensitivity detected by prolonged pH monitoring and Bernstein testing. Am J Gastroenterol. 2004;99:410–415.CrossRefPubMed Jung B, Steinbach J, Beaumont C, Mittal RK. Lack of association between esophageal acid sensitivity detected by prolonged pH monitoring and Bernstein testing. Am J Gastroenterol. 2004;99:410–415.CrossRefPubMed
14.
go back to reference Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(Suppl 1):112–117.CrossRefPubMed Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(Suppl 1):112–117.CrossRefPubMed
15.
go back to reference Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40:891–895.CrossRefPubMed Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40:891–895.CrossRefPubMed
16.
go back to reference Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population–the Kalixanda study. Aliment Pharmacol Ther. 2006;23:1725–1733.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population–the Kalixanda study. Aliment Pharmacol Ther. 2006;23:1725–1733.CrossRefPubMed
17.
go back to reference Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965–973.CrossRefPubMed Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965–973.CrossRefPubMed
18.
go back to reference Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–124.CrossRefPubMed Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–124.CrossRefPubMed
19.
go back to reference Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995;37:457–464.CrossRefPubMed Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995;37:457–464.CrossRefPubMed
20.
go back to reference Kamolz T, Velanovich V. Psychological and emotional aspects of gastroesophageal reflux disease. Dis Esophagus. 2002;15:199–203.CrossRefPubMed Kamolz T, Velanovich V. Psychological and emotional aspects of gastroesophageal reflux disease. Dis Esophagus. 2002;15:199–203.CrossRefPubMed
21.
go back to reference Thoua NM, Khoo D, Kalantzis C, Emmanuel AV. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2008;27:396–403.CrossRefPubMed Thoua NM, Khoo D, Kalantzis C, Emmanuel AV. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2008;27:396–403.CrossRefPubMed
22.
go back to reference Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989;96:683–689.PubMed Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989;96:683–689.PubMed
23.
go back to reference Richter JE. Role of the gastric refluxate in gastroesophageal reflux disease: acid, weak acid and bile. Am J Med Sci. 2009;338:89–95.CrossRefPubMed Richter JE. Role of the gastric refluxate in gastroesophageal reflux disease: acid, weak acid and bile. Am J Med Sci. 2009;338:89–95.CrossRefPubMed
24.
go back to reference Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;24(Suppl 2):10–16.CrossRefPubMed Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;24(Suppl 2):10–16.CrossRefPubMed
25.
go back to reference Katz PO. Review article: the role of non-acid reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:1539–1551.CrossRefPubMed Katz PO. Review article: the role of non-acid reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:1539–1551.CrossRefPubMed
26.
go back to reference Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981–988.CrossRefPubMed Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981–988.CrossRefPubMed
27.
go back to reference Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology. 2001;120:1588–1598.CrossRefPubMed Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology. 2001;120:1588–1598.CrossRefPubMed
28.
go back to reference Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-h esophageal pH and Bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci. 2008;53:2387–2393.CrossRefPubMed Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-h esophageal pH and Bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci. 2008;53:2387–2393.CrossRefPubMed
29.
go back to reference Byrne PJ, Mulligan ED, O’Riordan J, Keeling PW, Reynolds JV. Impaired visceral sensitivity to acid reflux in patients with Barrett’s esophagus. The role of esophageal motility. Dis Esophagus. 2003;16:199–203.CrossRefPubMed Byrne PJ, Mulligan ED, O’Riordan J, Keeling PW, Reynolds JV. Impaired visceral sensitivity to acid reflux in patients with Barrett’s esophagus. The role of esophageal motility. Dis Esophagus. 2003;16:199–203.CrossRefPubMed
30.
go back to reference Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett’s esophagus. Dig Dis Sci. 1997;42:1853–1858.CrossRefPubMed Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett’s esophagus. Dig Dis Sci. 1997;42:1853–1858.CrossRefPubMed
Metadata
Title
Non-Erosive Reflux Disease (NERD), Symptomatic and Asymptomatic Erosive Reflux Disease (ERD): From Hypersensitive to Hyposensitive Esophagus
Authors
Juanda L. Hartono
Choon-Seng Qua
Khean-Lee Goh
Publication date
01-01-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1275-5

Other articles of this Issue 1/2011

Digestive Diseases and Sciences 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.